View Older Stories View More Recent Stories

Jan 28, 2020 04:08PM Akcea Therapeutics (AKCA) and Ionis (IONS) report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 28, 2020 04:05PM Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 28, 2020 04:05PM Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 22, 2020 07:08AM Ionis Pharmaceuticals (IONS), Akcea Therapeutics (AKCA) Announce Positive Topline Phase 2 Results of AKCEA-APOCIII-L Rx
Jan 22, 2020 07:05AM Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 10, 2020 07:04AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Report Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx
Jan 10, 2020 07:00AM Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 10, 2020 07:00AM Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 9, 2020 07:05AM Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Jan 7, 2020 07:05AM Ionis' neurological franchise marks year of achievement
Jan 7, 2020 07:05AM /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
Jan 6, 2020 07:05AM Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference
Jan 2, 2020 08:01AM Akcea Therapeutics (AKCA) Reports Publication of Results from Phase 2 Study of AKCEA-APO(a)-LRx
Jan 2, 2020 08:00AM New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Jan 2, 2020 08:00AM New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Dec 19, 2019 07:08AM Ionis Pharmaceuticals (IONS) licenses investigational Alzheimer's therapy to Biogen (BIIB)
Dec 19, 2019 07:05AM Ionis licenses investigational Alzheimer's therapy
Dec 18, 2019 10:03PM Akcea Retains Rights to AKCEA-APOCIII-LRx
Dec 18, 2019 10:03PM Akcea Retains Rights to AKCEA-APOCIII-LRx
Dec 18, 2019 07:12AM Ionis Pharmaceuticals (IONS) appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
Dec 18, 2019 07:05AM Ionis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
Dec 16, 2019 07:09AM Akcea Therapeutics (AKCA) Announces Lynne Parshall, J.D. as Bpard Chair; Appoints Barbara Yanni to Board
Dec 16, 2019 07:00AM Akcea Therapeutics Announces New Appointments to its Board of Directors
Dec 16, 2019 07:00AM Akcea Therapeutics Announces New Appointments to its Board of Directors
Dec 4, 2019 07:00AM Akcea Announces Appointment of New Chief Operating Officer
Dec 4, 2019 07:00AM Akcea Announces Appointment of New Chief Operating Officer
Dec 2, 2019 07:05AM Ionis Pharmaceuticals to hold technology webcast
Nov 25, 2019 07:19AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Commence NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx
Nov 25, 2019 07:00AM Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
Nov 25, 2019 07:00AM Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
Nov 19, 2019 04:05PM Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
Nov 19, 2019 04:05PM Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
Nov 13, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
Nov 13, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
Nov 12, 2019 07:05AM Ionis Pharmaceuticals to present at upcoming investor conferences
Nov 6, 2019 07:00AM Ionis provides third quarter financial results and improved 2019 guidance
Nov 5, 2019 04:05PM Akcea Reports Financial Results and Highlights for Third Quarter 2019
Nov 5, 2019 04:05PM Akcea Reports Financial Results and Highlights for Third Quarter 2019
Nov 1, 2019 07:00AM Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
Nov 1, 2019 07:00AM Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
Oct 28, 2019 07:05AM Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
Oct 23, 2019 07:05AM Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences
Oct 23, 2019 07:00AM Akcea Announces Appointment of New Chief Commercial Officer
Oct 23, 2019 07:00AM Akcea Announces Appointment of New Chief Commercial Officer
Oct 22, 2019 07:05AM Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
Oct 22, 2019 07:00AM Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
Oct 22, 2019 07:00AM Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
Oct 10, 2019 07:05AM Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
Oct 9, 2019 06:52AM Ionis' (IONS) Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Oct 9, 2019 06:50AM Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
View More Recent Stories View Older Stories